Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice

Brain Research

Volumn 1167, Issue 1, 2007, Pages 31-41

  Crain, Stanley M ^a   Shen, Ke Fei ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Endogenous opioid analgesia: mu vs. kappa mediated; Excitatory Gs coupled opioid receptors; GM1 ganglioside regulated excitatory opioid receptors; Naloxone evoked hyperalgesia; Presynaptic inhibitory opioid autoreceptors; Ultra low dose naltrexone

Indexed keywords

GANGLIOSIDE GM1; GLYCOLIPID; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; NALOXONE; NALTREXONE; NORBINALTORPHIMINE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ANALGESIA; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HYPERALGESIA; LOW DRUG DOSE; MALE; MOUSE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; CHRONIC DISEASE; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; G(M1) GANGLIOSIDE; HYPERALGESIA; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTORS; OPIOID PEPTIDES; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME;

MUS;

EID: 34548130211     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.06.058     Document Type: Article

References (65)

1. Attal N., Kayser V., Jazat F., and Guilbaud G. Behavioral evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat. Brain Res. 494 (1989) 276-284
2. Basbaum A.I., Cruz L., and Weber E. Immunoreactive dynorphin B in sacral primary afferent fibers of the cat. J. Neurosci. 6 (1986) 127-133
3. Bourgoin S., Collin E., Benoliel J.J., Chantrel D., Mauborgne A., Pohl M., Hamon M., and Cesselin F. Opioid control of the release of Met-enkephalin-like material from the rat spinal cord. Brain Res. 551 (1991) 178-184
4. Burns G., Herz A., and Nikolarakis K.E. Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study. Neuroscience 36 (1990) 691-697
5. Celerier E., Laulin L.-P., Larcher A., Le Moal M., and Simonnet G. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 847 (1999) 18-25
6. Crain S.M., and Shen K.-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11 (1990) 77-81
7. Crain S.M., and Shen K.-F. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Res. 575 (1992) 13-24
8. Crain S.M., and Shen K.-F. After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition. J. Pharmacol. Exp. Ther. 260 (1992) 182-186
9. Crain S.M., and Shen K.-F. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10540-10544
10. Crain S.M., and Shen K.-F. Chronic morphine-treated sensory ganglion neurons remain supersensitive to the excitatory effects of naloxone for months after return to normal culture medium: an in vitro model of 'protracted opioid dependence'. Brain Res. 694 (1995) 103-110
11. Crain S.M., and Shen K.-F. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol. Sci. 19 (1998) 358-365
12. Crain S.M., and Shen K.-F. GM1 ganglioside-induced modulation of opioid receptor-mediated functions. Ann. N.Y. Acad. Sci. 845 (1998) 106-125
13. Crain S.M., and Shen K.-F. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions. Brain Res. 856 (2000) 227-235
14. Crain S.M., and Shen K.-F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84 (2000) 121-131
15. Crain S.M., and Shen K.-F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low naltrexone, unmasking potent opioid analgesia. Brain Res. 888 (2001) 75-82
16. Crain S.M., and Shen K.-F. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res. 995 (2004) 260-266
17. Fournie-Zaluski M.C., Chaillet P., Bouboutou R., Coulaud A., Cherot P., Waksman G., Costentin J., and Roques B.P. Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur. J. Pharmacol. 102 (1984) 525-528
18. Goldberg S.R., and Schuster C.R. Nalorphine: increased sensitivity of monkeys formerly dependent on morphine. Science 166 (1969) 1548-1549
19. Hökfelt T., Shi T.-J.S., Cui J.-G., Meyerson B., Linderoth B., Tong Y.-G., Wang H.F., Xu Z.-Q.D., Ju G., Grant G., and Zhang X. Phenotypic changes induced in dorsal root ganglion neurons by nerve injury. In: Kalso E., McQuay H.J., and Wiesenfeld-Hallin Z. (Eds). Opioid Sensitivity of Chronic Noncancer Pain. Progress in Pain Research and Management vol. 14 (1999), IASP Press, Seattle 145-161
20. Jaffe J.H., and Martin W.R. Opioid analgesics and antagonists. Goodman and Gilman's Pharmacologic Basis of Therapeutics. 8th Ed. (1990) 485-521
21. Jhamandas K., Yaksh T.L., and Go V.L.W. Acute and chronic morphine modifies the in vivo release of methionine enkephalin-like immunoreactivity from the cat spinal cord and brain. Brain Res. 297 (1984) 91-103
22. Jhamandas K.H., Marsala M., Ibuki T., and Yaksh T.L. Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J. Neurosci. 16 (1996) 2758-2766
23. Jiang Q., Heyman J.S., Sheldon R.J., Koslo J., and Porreca F. Mu antagonist and kappa agonist properties of β-funaltrexamine (β-FNA) in vivo: long-lasting spinal analgesia in mice. J. Pharmacol. Exp. Ther. 252 (1990) 1006-1011
24. Kayser V., and Guilbaud G. Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats. Brain Res. 226 (1981) 344-348
25. Kayser V., Besson J.M., and Guilbaud G. Analgesia produced by low doses of the opiate antagonist naloxone in arthritic rats is reduced in morphine-tolerant animals. Brain Res. 371 (1986) 37-41
26. Kayser V., Benoist J.M., Neil A., Gautron M., and Guilbaud G. Behavioural and electrophysiological studies on the paradoxical antinociceptive effects of an extremely low dose of naloxone in an animal model of acute and localized inflammation. Exp. Brain Res. 73 (1988) 402-410
27. Kayser V., Fournie-Zaluski M.C., Guilbaud G., and Roques B.P. Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin degrading enzymes) systemically administered in normal and arthritic rats. Brain Res. 497 (1989) 94-101
28. Kim D.H., Fields H.L., and Barbaro N.M. Morphine analgesia and acute physical dependence: rapid onset of two opposing, dose-related processes. Brain Res. 516 (1990) 37-40
29. Langer S.Z. Presynaptic regulation of the release of catecholamines. Pharmacol. Rev. 32 (1981) 337-362
30. Langer S.Z. 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol. Sci. 18 (1997) 95-99
31. Mao J., Price D.D., and Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62 (1995) 259-274
32. Nestler E.J. From neurobiology to treatment: progress against addiction. Nat. Neurosci. Suppl. 5 (2002) 1076-1079
33. Nikolarakis K.E., Almeida O.F.X., Yassouridis A., and Herz A. Presynaptic auto- and allelo-receptor regulation of hypothalamic opioid peptide release. Neuroscience 31 (1989) 269-273
34. Noble F., Soleilhac J.M., Soroca-Lucas E., Turcaud S., Fournie-Zaluski M.C., and Roques B.P. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261 (1992) 181-190
35. Noble F., Fournie-Zaluski M.C., and Roques B.P. Paradoxical analgesia induced by low doses of naloxone is not potentiated by complete inhibition of enkephalin degradation. Neuropharmacology 33 (1994) 135-140
36. North R.A. Opioid receptor types and membrane ion channels. Trends Neurosci. 9 (1986) 114-117
37. Olmstead M.C., and Burns L.H. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology 181 (2005) 576-581
38. Paterson S.J., Robson L.E., and Kosterlitz H.W. Classification of opioid receptors. Br. Med. Bull. 39 (1983) 31-36
39. Powell K.J., Abul-Husn N.S., Jhamandas A., Olmstead M.C., Beninger R.J., and Jhamandas K. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J. Pharmacol. Exp. Ther. 300 (2002) 588-596
40. Redmond Jr. D.E., and Krystal J.H. Multiple mechanisms of withdrawal from opioid drugs. Ann. Rev. Neurosci. 7 (1984) 443-478
41. Scheideler M.A., and Dawson G. Direct demonstration of the activation of UDP-N-acetylgalactosamine:[GM3]N-acetylgalactosaminyltransferase by cyclic AMP. J. Neurochem. 46 (1986) 1639-1643
42. Shen K.-F., and Crain S.M. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res. 491 (1989) 227-242
43. Shen K.-F., and Crain S.M. Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Res. 525 (1990) 225-231
44. Shen K.-F., and Crain S.M. Cholera toxin-B subunit blocks opioid excitatory effects on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions. Brain Res. 531 (1990) 1-7
45. Shen K.-F., and Crain S.M. Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid "dependence" without tolerance. Brain Res. 597 (1992) 74-83
46. Shen K.-F., and Crain S.M. Nerve growth factor rapidly prolongs the action potential of mature sensory neurons in culture and this effect requires activation of Gs-coupled excitatory kappa opioid receptors on these cells. J. Neurosci. 14 (1994) 5570-5579
47. Shen K.-F., and Crain S.M. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 757 (1997) 176-190
48. Shen K.-F., and Crain S.M. Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence. Brain Res. 919 (2001) 20-30
49. Shen K.-F., Crain S.M., and Ledeen R.W. Brief treatment of sensory ganglion neurons with GM1 ganglioside enhances the efficacy of opioid excitatory effects on the action potential. Brain Res. 550 (1991) 130-138
50. Starke K., Gothert M., and Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 69 (1989) 864-989
51. Tallarida R.J., and Murray R.B. Manual of Pharmacologic Calculations with Computer Programs (1987), Springer-Verlag, New York
52. Tilson H.A., Rech R.H., and Stolman S. Hyperalgesia during withdrawal as a means of measuring the degree of dependence in morphine dependent rats. Psychopharmacologia 28 (1973) 287-300
53. Tong Y.-G., Wang H.F., Ju G., Grant G., Hökfelt T., and Zhang X. Increased uptake and transport of cholera toxin B-subunit in dorsal root ganglion neurons after peripheral axotomy: possible implications for sensory sprouting. J. Comp. Neurol. 404 (1999) 143-158
54. Ueda H., Fukushima N., Kitao T., Ge M., and Takagi H. Low doses of naloxone produce analgesia in the mouse brain by blocking presynaptic autoinhibition of enkephalin release. Neurosci. Lett. 65 (1986) 247-252
55. Ueda H., Fukushima N., Ge M., Takagi H., and Satoh M. Presynaptic opioid kappa-receptor and regulation of the release of met-enkephalin in the rat brainstem. Neurosci. Lett. 81 (1987) 309-313
56. Waldhoer M., Bartlett S.E., and Whistler J.L. Opioid receptors. Ann. Rev. Biochem. 73 (2004) 953-990
57. Wang H.-Y., and Burns L.H. Gβγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J. Neurobiol. 66 (2006) 1302-1310
58. Wang H.-Y., Friedman E., Olmstead M.C., and Burns L.H. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gβγ signaling. Neuroscience 135 (2005) 247-261
59. Ward S.J., and Takemori A.E. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J. Pharmacol. Exp. Ther. 224 (1983) 525-530
60. Ward S.J., Portoghese P.S., and Takemori A.E. Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J. Pharmacol. Exp. Ther. 220 (1982) 494-498
61. Wikler A. Opioid Dependence (1980), Plenum, New York
62. + currents. J. Neurosci. Res. 42 (1995) 493-503
63. Wu G., Lu Z.-H., and Ledeen R.W. Interaction of δ-opioid receptor with GM1 ganglioside: conversion from inhibitory to excitatory mode. Mol. Brain Res. 44 (1997) 341-346
64. Wu G., Lu Z.-H., Tzongjer J.W., Howells R.D., Christoffers K., and Ledeen R.W. The role of GM1 ganglioside in regulating excitatory opioid effects. Ann. N.Y. Acad. Sci. 845 (1998) 126-138
65. 1A receptor-mediated inverse tolerance. Trends Pharmacol. Sci. 24 (2003) 634-639